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Protein–protein interactionsArginine-rich cell-penetrating peptides (CPP) are widely employed as delivery vehicles for a large variety of
macromolecular cargos. As a mechanism-of-action for induction of uptake cross-linking of heparan sulfates
and interaction with lipid head groups have been proposed. Here, we employed a multivalent display of the
CPP nona-arginine (R9) on a linear dextran scaffold to assess the impact of heparan sulfate and lipid interactions
on uptake and membrane perturbation. Increased avidity through multivalency should potentiate molecular
phenomena that may only play a minor role if only individual peptides are used. To this point, the impact of
multivalency has only been explored for dendrimers, CPP-decorated proteins and nanoparticles. We reasoned
thatmultivalency on a linear scaffoldwouldmore faithfullymimic the arrangement of peptides at themembrane
at high local peptide concentrations. On average, ﬁve R9 were coupled to a linear dextran backbone. The conju-
gate displayed a direct cytoplasmic uptake similar to free R9 at concentrations higher than 10 μM. However, this
uptake was accompanied by an increased membrane disturbance and cellular toxicity that was independent of
the presence of heparan sulfates. In contrast, for erythrocytes, the multivalent conjugate induced aggregation,
however, showed only limited membrane perturbation. Overall, the results demonstrate that multivalency of
R9on a linear scaffold strongly increases the capacity to interactwith theplasmamembrane.However, the induc-
tion of membrane perturbation is a function of the cellular response to peptide binding.
© 2014 Published by Elsevier B.V.1. Introduction
Conjugation to cell-penetrating peptides (CPPs) is considered a
highly promising strategy to mediate cellular delivery of molecules
that otherwise poorly enter cells [1–3]. Natural and synthetic CPPs are
continuously being (re-)designed to improve delivery [4,5]. In contrast
to the original concept of the CPP acting as a Trojan horse that passagesarginine; Dex-(R9)5, pentavalent
odide; N.A., numerical aperture;
A, bovine serum albumin
ry (286), Radboud Institute for
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es, Albert-Ludwigs-Universität
ty of Zurich, Winterthurerstrassepassively through the plasma membrane by virtue of its structural
characteristics it has become clear that with the exception of direct
membrane permeation at low concentrations [6,7] CPPs actively induce
cellular uptake [8]. In particular for large molecular weight cargos,
endocytosis is the route of uptake [9]. Furthermore, at concentrations
above about 10 μM, arginine-rich CPPs induce activation of acid sphin-
gomyelinase, which leads to rapid cytoplasmic import via ceramide-
rich membrane microdomains [10,11].
While the molecular mechanism underlying the activation of acid
sphingomyelinase has not been resolved, for induction of endocytosis,
it has been proposed that binding to negatively charged oligosaccha-
rides of the glycocalyx leads to a clustering of syndecans [12], which
activates Rac-dependent actin remodeling [13]. However, uptake is
also observed for cells that are poor in glycosaminoglycans such as
Jurkat T cell leukemia cells which calls for the involvement of additional
processes [11].
Strikingly, in spite of its activity as a CPP, for nona-arginine (R9) little
to no enrichment at cellular membranes is observed. Only when
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is visible which can be attributed to the interaction with glycosamino-
glycans [14]. This indicates that in spite of a documented ability to
interact with the head groups of the lipid bilayer and the capacity to
partition into a hydrophobic environment in the presence of negatively
charged chelating groups [15–17], on cells there is little enrichment at
the level of the plasma membrane. Also, among a panel of nine tested
CPPs R9 had the least membrane-disruptive potential [18], overall indi-
cating that enrichment at the plasmamembrane plays only a small role
in the uptake of this CPP.
The geometry in which positive charge is presented greatly inﬂu-
ences uptake efﬁciency. On one hand, it has been demonstrated that
import can be enhanced through rigidifying the peptide backbone
through cyclization [19]. On the other hand, multivalency is a well-
established principle to potentiate molecular interactions through
introduction of avidity [20–22]. Multivalent interactions in nature
include binding of DNA at several sites by transcription factors, like
the retinoid X receptor [20] or immunogenic recognition bymultivalent
antibodies such as IgM [23]. In the context of CPPs, oligoarginines are an
example for a multivalent display of the guanidino-group and up to a
certain length, activity of oligoarginines increases with the number
of residues [24,25]. With respect to a multivalent display of CPPs,
multivalency has been investigated for TAT, oligolysine, HSV-1
VP22, oligoarginine, Antp, (reviewed in Ref. [26]), zinc coordinated
oligotyrosine peptides [27] and recently for TP10, pVEC and polyproline
helix SAP [28]. A tetravalent presentation of deca-arginine fused to the
p53 protein was shown to improve delivery efﬁciency even at low
concentrations without increasing toxicity [29]. In the latter study, this
increased activity was associated with enhanced interactions with cell
surface heparan sulfates. However, these multivalent arrangements
were either based on globular scaffolds or branched dendrimers,
geometries that conﬁne the area of interaction with the membrane
components of the cell. To be effective for promoting uptake, a stretch
of arginines has to be present. A dispersed presentation of individual
arginines on a polymer results in considerably reduced uptake also at
higher charge density [30]. Overall, the multivalent geometries that
have been investigated so far for CPPs are more restricted than those
addressed for antimicrobial peptides for which presentation along
linear scaffolds has also been investigated, already [31].
In all these applications, the multivalent CPPs were well tolerated,
showing little signs of toxicity. Also, individual oligoarginine peptides
are generally well tolerated to concentrations in the mean micromolar
range [11,24].
Beyond yielding a beneﬁt in efﬁciency, so far, themultivalent display
of CPPs has yielded little insights into the molecular mechanisms
triggering import. Also, no functional characteristics were reported
that differed greatly for those of the individual CPPs. As for individual
CPPs, it has been proposed that the multivalent systems crosslink
glycosaminoglycans followed by endocytosis [32]. This may be due to
the globular nature of these structures that renders them very similar
to CPPs linked to macromolecules.
Therefore, in the present study we compared a multivalent conﬁgu-
ration of nona-arginine (R9) in which on average ﬁve copies of the CPP
were coupled to a linear and ﬂexible dextran backbone (Dex-(R9)5) to
the monovalent R9 counterpart. We hypothesized that in comparison
to multivalent displays on globular structures, this conﬁguration
would result in contact of the molecule with a larger surface area of
the plasma membrane or in a structurally adaptive binding due to the
ﬂexibility of the dextran backbone. In particular, we hoped that this
conﬁguration would shed further light into the structural requirements
for triggering the rapid sphingomyelinase-dependent uptake mecha-
nism. All data presented so far, indicated that this import route is
restricted to free CPPs or CPPs conjugated to small molecular weight
cargo [9,10].
Next to addressing uptake and toxicity for HeLa and Jurkat cells
we also included human erythrocytes in our studies. These cellslack endocytosis and should therefore reveal to which degree a
membrane-disruptive activity is a function of the conjugate–membrane
interaction or the triggering of a cellular response. Since multivalency
can generate strong interactions for low afﬁnity binders, we also
addressed whether inside the cell the multivalent display of R9 leads
to the disruption of protein–protein interactions. Our results demon-
strate that the multivalent display strongly enhances interactions with
the plasma membrane. The restriction of toxicity to cells that show
uptake demonstrates that toxicity is a consequence of the reaction of
the cells to these conjugates. Interactions of the conjugates with the
plasma membrane alone are insufﬁcient to evoke strong toxicity.
2. Materials and methods
2.1. Reagents
Nona-arginine (R9) with an amidated C-terminus and an N-terminal
carboxyﬂuoresceinwas purchased fromEMCmicrocollections (Tübingen,
Germany). Dex-(R9)5 was synthesized using a 10 kDa dextran (Dex)
backbone comprising on average of 62 glucose monomers. Carboxyethyl
groups were introduced using acrylamide followed by amide hydrolysis
to form 2-carboxyethyl dextran (CED). N-(2-aminoethyl)maleimide was
synthesized and coupled to the modiﬁed polymer. Using maleimide-
thiol coupling, in a single stepN-cysteinyl-lysinyl-5(6)-carboxyﬂuoresce-
in and N-cysteinylnona-arginine amide were coupled to the modiﬁed
dextran achieving an average loading of ﬁve nona-arginine peptides and
one ﬂuorophore per polymer as determined by quantitative amino acid
analysis and NMR [22]. Dex-(R9)5 had a ﬁnal molecular weight of
22 kDa (for details see SI, Figure S1.1 and S1.2). Dex and CED were used
as negative controls. Imipramine, resazurin and Tween-20 were from
Sigma-Aldrich (Zwijndrecht, the Netherlands). Propidium iodide and
Alexa-647-labeled Annexin-V were from Invitrogen (Eugene, USA) and
Ficoll-Paque from GE Healthcare (Uppsala, Sweden). Complete Ringer
(pH 7.4) solution was prepared using 32 mM HEPES, 125 mM NaCl,
5 mM glucose, 5 mM KCl, 1 mMMgSO4, 2.5 mM CaCl2.
2.2. Tissue culture
Jurkat T cell leukemia cells (ACC-282, DSMZ, Braunschweig, Germany)
and HeLa cells (CCL-2, ATCC, LGC Standards, Wessel, Germany) were
cultured in RPMI1640 with stable glutamine and 2.0 g/L NaHCO3
(PAN Biotech, Aidenbach, Germany) supplemented with 10% heat
inactivated fetal bovine serum (FBS; PAN Biotech). Cells were main-
tained at 37 °C in a humidiﬁed incubator containing 5% CO2. Jurkat
cells were passaged every 2–3 days when the cells had grown to a
density of approximately 4 * 105 cells/mL while HeLa cells were
passaged every 2 days at around 80%–90% conﬂuency.
2.3. Confocal microscopy
Confocal laser scanning microscopy was performed on a TCS SP5
confocal microscope (Leica Microsystems, Mannheim, Germany)
equipped with an HCX PL APO 63x 1.2 N.A. water immersion lens.
Cells weremaintained at 37 °C on a temperature-controlledmicroscope
stage. For multichannel recordings with propidium iodide (PI) or
Annexin-V in addition to the labeled R9 or Dex-(R9)5, images were
recorded using the 488 nm line of an argon-ion laser and a HeNe 561
or 633 nm laser. To avoid crosstalk, ﬂuorescence was recorded sequen-
tially where necessary.
2.4. Dex-(R9)5 uptake
HeLa cells (4 * 104/well) were seeded in 8-well microscopy cham-
bers (Nalge Nunc International, New York, USA), 24 hours prior to
peptide addition. Cells were incubated with 4 μM Dex-(R9)5 or 20 μM
R9 in RPMI 1640 supplemented with 10% FBS (heat inactivated) for
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cells were pre-incubated for 45 minutes with 30 μM imipramine in
RPMI 1640 without serum. For subsequent incubation with peptide,
30 μM imipramine was co-incubated with peptide in medium contain-
ing 10% FBS. Cells were washed twice with medium. To check for
membrane-integrity as well as cell viability, cells were incubated with
5 μg/mL PI and immediately imaged bymicroscopy. For studies in Jurkat
cells, 200 μL of a 5 * 105 cells/mL Jurkat cell suspension in RPMI 1640
without phenol red and 10% FBS were transferred per well into 8-well
microscopy chambers coated with a 20 μg/mL ﬁbronectin solution in
PBS for 30 minutes at room temperature (RT). At time point t = 0,
5 μM or 10 μM of R9 or 1 μM or 2 μM of Dex-(R9)5 were added to
the wells.
2.5. Image enhancement
Image J (version 1.46j, freeware, NIH)was used tomodify brightness
and contrast of the confocal microscopy images.
2.6. Image quantiﬁcation
Image J (version 1.46j, freeware, NIH) was used to analyze the
confocal microscopy images. Images were ﬁrst smoothened and then
converted into a binarymask using thresholds for ﬂuorescence intensity
and size. This mask was used to extract cell-associated ﬂuorescence in
the original background-corrected images. To separate adjacent cells a
watershed function was applied to the binary mask. Mean intensities
(represented as intracellular ﬂuorescence) were measured from all
cells within one image frame (at least 50 cells were analyzed).
2.7. Cytotoxicity assay
HeLa cells (7.5 * 103 cells/well) were seeded in 96-well microtiter
plates and grown overnight. The next day, cells were treated with
varying concentrations of R9/Dex-(R9)5/Dex/CED for 24 hours at
37 °C. Cell viability was measured using the resazurin assay.
Resazurin is a non-ﬂuorescent dye that is reduced to the highly
ﬂuorescent resoruﬁn by metabolically active cells [33,34]. Cells
were incubated with resazurin (100 μg/mL) for 4 hours. Fluores-
cence was read with a Synergy 2 single-channel microplate reader
(BioTek Instruments, Winooski, USA). Percentage cell viability was
calculated as [(Ti− T0)/(C− T0)] × 100 for concentrations in which
Ti ≥ T0 and [(Ti− T0)/T0] × 100 for concentrations in which Ti b T0.
Ti is the ﬂuorescence of the test-well after a 24-hour period of exposure
to the treatment, T0 is the ﬂuorescence at time zero (i.e. before addition
of compounds) and C is the ﬂuorescence after 24 hours of cell seeding.
This parameter can have values from +100 to−100 [35].
2.8. Effect of Dex-(R9)5 on erythrocytes
Bloodwas drawn fromhealthy volunteers. The studywas performed
following the guidelines of the local medical ethical committee and in
accordance with the declaration of Helsinki. Written informed consent
was obtained from all blood donors participating in this study. To isolate
erythrocytes, fresh blood was centrifuged at 1500×g for 10 minutes.
Erythrocyte pellets were washed twice with calcium-free Ringer to
prevent complement activation and once with complete Ringer. Eryth-
rocytes were resuspended in 100 μL Ringer and diluted to 1 million
cells/well in chambered coverslips. R9 or Dex-(R9)5 were added to
the cells in an equal volume of Ringer at the indicated concentrations
and imaged by time lapse confocal microscopy. Alexa-647-labeled
Annexin-V was also added at a dilution of 1:25. Cells were manually
counted to quantify exposure of phosphatidylserine, changes in mor-
phology and lysis.2.9. Impact of Dex-(R9)5 on protein–protein interactions
In order to induce activation-dependent protein complex forma-
tion, Jurkat cells were treated with 0.5 mM of the broad-range
phosphatase inhibitor pervanadate (PV) in HBS or as a control with
HBS for 10 minutes at 37 °C. Cell lysates were prepared by
suspending 1 million cells per subarray in 50 μL lysis buffer (1% Triton
X-100, 50 mM n-octyl-D-glucopyranoside (Fluka, Taufkirchen,
Germany), 20 mM Tris, 1 mM EDTA, 150 mM NaCl, 1 mM Na3VO4,
pH 7.5, and complete protease inhibitor cocktail (Roche Applied
Science, Mannheim, Germany)). N-octyl-D-glucopyranoside ensured
the efﬁcient extraction of signaling proteins from lipid rafts. After lysis
on ice for 1 hour, the crude lysates were cleared by centrifugation at
20,000×g at 4 °C for 15 minutes. Afterwards, 5 μM R9 or 1 μM Dex-
(R9)5 was added to cell lysate. Finally, lysateswere incubated onmicro-
arrays as described below. Peptide microarrays presenting known
interaction motifs for proteins involved in T cell signaling were
prepared as described before [36]. One microarray substrate carried
16 identical subarrays. For incubation of these subarrays with different
samples a 16-well clip-on frame (ProPlate Multiarray System, Grace
Biolabs, Molecular Probes, Eugene, OR, USA) was mounted onto the
microarray slides. Microarrays were incubated with 50 μL of lysate
from 1 million cells per subarray for 1 hour at 4 °C and washed three
times with washing buffer (PBS, 0.05% (wt/vol) BSA, 0.05% (wt/vol)
Tween-20). For the detection of bound protein by indirect immunoﬂu-
orescence, microarrays were incubated with 2 μg/mL primary antibody
(α-PLCγ1, Santa Cruz Biotechnology, Heidelberg, Germany, sc-81;
α-LAT, Millipore 05-770, Schwalbach, Germany) diluted in washing
buffer for 15 minutes at RT and washed three times with washing
buffer. Afterwards,microarrayswere incubatedwith 1 μg/mL secondary
goat-anti-rabbit antibody conjugated with Alexa-633 and goat-α-
mouse secondary antibody conjugated with Alexa-546 (A21070,
A11003, Invitrogen) for 10 minutes at RT followed by a ﬁnal washing
step with washing buffer. As a negative control, one subarray was
immunostained without incubation with lysate. Finally, microarrays
were dried with nitrogen and scanned (ProScanArray, PerkinElmer
Life Sciences, Waltham, MA, USA). Processing of the signals occurred
as described previously using ArrayPro Analyzer (Media Cybernetics,
Silver Spring, MD, USA) [36]. Signals on microarrays were obtained by
subtraction of the median signal of a local ring-shaped background
from the mean of signal intensities on a peptide spot.
3. Results
3.1. Dex-(R9)5 exhibits sphingomyelinase-dependent uptake
and nucleolar staining
Previous work on multivalent cationic peptides and protein trans-
duction domains elucidated that multivalency greatly improves cellular
import of these conjugates [29]. Uptake occurred by endocytosis,
consistent with the general assumption according to which macromo-
lecular CPP-complexes and conjugates are taken up along this route
and direct translocation and rapid cytoplasmic uptake are restricted to
free CPPs and CPPs conjugated to small molecular weight cargo [9,10].
However, so far, multivalent conﬁgurations were nanoparticulate,
potentially restricting the ability of thesemolecules to engagewith larger
areas of the plasma membrane. Therefore, we here synthesized a highly
ﬂexible multivalent CPP conjugate by coupling on average ﬁve copies of
nona-arginine to a 10-kDa dextran backbone. A ﬂuorescein moiety was
introduced to monitor the cellular distribution and uptake.
HeLa cells were incubated with 20 μM R9 or 4 μM Dex-(R9)5, corre-
sponding to the same concentration of CPP and the distribution of
ﬂuorescence was observed by confocal microscopy in living cells. As
reported before, at this concentration R9 exhibited a uniform homoge-
neous staining of cells with only few endocytic vesicles [11] (Fig. 1,
also SI, Figure S2). This is the typical distribution of ﬂuorescence
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ation zones [10,11]. Also for Dex-(R9)5 cells showed an intense cyto-
plasmic ﬂuorescence, however, this ﬂuorescence was distributed
less homogenously than for R9 and also showed a distinct nucleolar
staining as was observed for the D-Amino acid analog of R9 [14].
Areas of more intense ﬂuorescence were reminiscent of nucleation
zones. Also, cell shapes were more irregular for Dex-(R9)5-treated
cells than for cells incubated with free peptide, suggesting a stronger
membrane-perturbing effect of themultivalent conjugate. Interestingly,
cell-associated ﬂuorescence for Dex-(R9)5 was about the same as for R9
(Fig. 1B). Considering, that one conjugate carried one ﬂuorophore for
ﬁve peptides, this indicates that on a per-peptide basis, uptake was
in about the same range (maximum ﬁve fold higher per peptide)
than for R9.
Sensitivity to imipramine which acts as an inhibitor of acid sphin-
gomyelinase was identiﬁed as a characteristic of nucleation zone-
dependent uptake [10]. However, as detailed above this route of uptake
was limited to free CPPs or CPPs conjugated to small cargos [9,10]. A
polymer-conjugate of similar size but with only 3 nona-arginines was
unable to enter via this route [10,37]. To investigate whether Dex-
(R9)5 nevertheless exploited this mechanism or whether uptakeFig. 1. Cellular distribution and imipramine-sensitive uptake of Dex-(R9)5. (A) Following a 45
incubatedwith 20 μMR9 or 4 μMDex-(R9)5 for 20 minutes at 37 °C in the presence or absence
copy settings for image acquisition of all samples were adjusted for R9 to avoid saturation. One
representative experiment of at least three experiments is shown. Homogenous staining of R9
Brightness and contrast have been adjusted for visualization purposes using the same paramete
images. (B) Imipramine-sensitive uptake quantiﬁed from A (raw, unmodiﬁed images); at leastoccurred as a consequence of membrane disruption, uptake was
assessed in the presence of imipramine. Imipramine abolished cytoplas-
mic ﬂuorescence of both, R9 and Dex-(R9)5 in a major part of cells
supporting a role of sphingomyelinase-dependent uptake in both
cases (Fig. 1, SI Figure S2). To exclude that the reducing effect was due
to an interference of the imipramine with the peptides/conjugate at
the plasma membrane, we compared the effect of a pre-incubation
with imipramine with the one of a pre- and co-incubation. Indeed, in
the latter case the reduction was stronger demonstrating that some
direct interference occurs (SI, Figure S3).
Considering the more irregular cell shape for the Dex-(R9)5-treated
cells we also probed for membrane damage which does not occur
for sphingomyelinase-dependent uptake [11]. Cells were exposed to
conjugates for 20 minutes and after washing PI was added to monitor
changes in membrane integrity. For the multivalent conjugate there
was a loss of membrane integrity for some cells (Fig. 2). Remarkably,
the number of PI-positive cells was decreased by the presence of
imipramine indicating that membrane damage is a consequence of
uptake rather than the interaction of the conjugate with the plasma
membrane (Fig. 2). This increased membrane-disruptive potential was
also reﬂected by a higher reduction in cell viability over a 24-hourminute pretreatment with/without imipramine (imi) in serum-free RPMI, HeLa cells were
of 30 μM imipramine followed bywashing and imagingwith confocal microscopy. Micros-
confocal slice is shown for all themicroscopy images. Scale bars correspond to 20 μm. One
is observed in 70% of cells (for whole ﬁeld-of-view of images see SI, Section S2, Figure S2).
rs for ﬂuorescence images and parameters to yield the best possible result for transmission
50 cells were counted. Error bars represent S.E.
Fig. 2.Uptake of Dex-(R9)5 is associated with only partial loss of membrane integrity. HeLa cells were treatedwith 4 μMDex-(R9)5 or 20 μMR9 for 20 minutes at 37 °C in the presence or
absence of 30 μM imipramine (imi) as stated before. After washing, PI (5 μg/mL) was added and cells were imaged without any further washing step by confocal microscopy. Tween-20
(0.25%) was used as a positive control for membrane disruption. Scale bars correspond to 20 μm. Brightness and contrast have been adjusted for visualization purposes using the same
parameters for ﬂuorescence images and parameters to yield the best possible result for transmission images.
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1 μM Dex-(R9)5 (corresponding to an overall peptide concentration of
5 μM) compared to 11 μM R9 over 24 hours. Dex and CED, which
were used as negative controls, did not show any signiﬁcant toxicity
indicating that neither the native nor the carboxyethylated dextran
backbone were responsible for the toxicity of Dex-(R9)5.
HeLa cells have a high density of heparan sulfates and other
negatively charged oligosaccharides [38] that serve as binding sites for
arginine-rich peptides [39]. We were therefore interested to assess the
impact of the linear, multivalent Dex-(R9)5 conjugate on Jurkat T cell
leukemia cells that express signiﬁcantly lower levels of heparan sulfates
[38]. At 5 μM (Fig. 4A and SI movie S4-M1), over the time course of the
experiment, R9 showed only internalization in a few cells with no signs
of toxicity. At 10 μM(Fig. 4B andmovie S4-M2), R9 ﬂuorescence rapidly
entered the cytoplasm reminiscent of nucleation zone-dependent
uptake [11]. For the free peptide, uptake occurred in the absence ofFig. 3. Multivalency of nona-arginine in Dex-(R9)5 increases toxicity. HeLa cells were
treated with the indicated concentrations of Dex-(R9)5 (with respect to the polymer
backbone) for 24 hours and cell viability was determined using a resazurin assay in
comparison to R9. CED (carboxyethyl dextran) and Dex (native dextran) were used as
controls. Data represents average ± SEM of three independent experiments, each carried
out in triplicate, which means N= 9.visible membrane staining. In contrast, Dex-(R9)5 (Fig. 4C and D and
SI movies S4-M3, S4-M4), already at a concentration of 1 μM with
respect to backbone caused massive membrane staining and cell
death accompanied by formation of membrane blebs. Control CED had
no effect on cell viability (Fig. 4E and SI movie S4-M5).
3.2. Dex-(R9)5 but not R9 binds to erythrocyte membranes and
induces cell aggregation
Concomitant with increased toxicity, for Dex-(R9)5 we observed an
increased membrane staining which was absent for R9. Two possible
explanations were considered for this membrane staining. First, the
multivalent display of guanidino-groups could afford sufﬁcient avidity
for interaction with the plasma membrane also in the absence of a
massive disturbance. Second, staining could be a consequence of the
membrane-disruptive effect of the conjugate, leading to exposure of
negatively charged phosphatidylserine that would then in turn lead to
a membrane accumulation of the peptide. In this second case, it would
be interesting to learn whether disruption was again a function of the
peptide alone, or of the cellular response to the peptide. In order to
distinguish these mechanisms, we employed erythrocytes as a model
system. In contrast to nucleated cells, erythrocytes do not exhibit
endocytosis. Cationic amphipathic, membrane-active peptides like
mastoparan [40], gramicidin S [41], mellitin [41] and several other
drugs [42] have been shown to cause shape changes and cell lysis in
erythrocytes. For CPPs only few studies about the impact on erythro-
cytes exist. One study addressed the uptake of α- and β-oligoarginines
in normal versus parasite-infected erythrocytes [43] demonstrating
that both types of oligoarginines did not enter healthy erythrocytes
but only the parasite-infected ones. TAT only showed activity in combi-
nation with a phototoxic effect [44].
Erythrocyteswere incubatedwith Dex-(R9)5 in the presence of ﬂuo-
rescently labeled Annexin-V and the impact on erythrocytemorphology
and phosphatidylserine exposure was determined by time lapse confo-
cal microscopy (Figs. 5A, SI Figure S5.1 andmovie S5-M6). Themultiva-
lent conjugate bound to the membrane almost immediately after
addition. For 37% of the cells (3 independent experiments with 605
cells in total) this bindingwas followed by phosphatidylserine exposure
(detected by binding of Annexin-V), indicating that disruption of
Fig. 4. Time lapse microscopy of themembrane-disruptive behavior of Dex-(R9)5 in Jurkat cells. Jurkat cells were exposed to (A) 5 μMR9, (B) 10 μMR9, (C) 1 μMDex-(R9)5 and (D) 2 μM
Dex-(R9)5 at 37 °C and ﬂuorescence and transmission recordedwith 2 images/min. Concentrations of Dex-(R9)5 werewith respect to the polymer backbone. CED of 2 μM(E)was used as
control. Peptide/conjugatewas added at the time of image acquisition by careful pipetting into the sample. The start of exposure of cells to peptide/conjugate is visible from the increase in
ﬂuorescence outside the cells. Scale bars correspond to 25 μm. Also see SI, movies S4-M1 to M5.
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Fig. 5. Dex-(R9)5 induces erythrocyte aggregation and phosphatidylserine exposure. (A) 0.6 μMDex-(R9)5 and 6 μMR9were added to erythrocytes in Ringer and imaged by confocal mi-
croscopy at 37 °C after 20 minutes. Annexin-V was also added to cells at a dilution of 1:25 to stain for phosphatidylserine. Scale bars correspond to 50 μm. (B) Erythrocyte aggregates
formed after the addition of 0.6 μM Dex-(R9)5. The scale bar corresponds to 10 μm. Also see SI movies S5-M6 and M7.
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of strong binding of the conjugates. Phosphatidylserine exposure
was followed by disruption of membrane integrity as visible by entry
of ﬂuorescence into the cytoplasm. By 20 minutes, 9% of the cells were
lysed. Interestingly, within the ﬁrst 2 minutes erythrocytes also formed
aggregates (Fig. 5B, SI Figure S5.1, movie S5-M6) that incorporated 50%
of cells at 0.6 μMof Dex-(R9)5. In contrast, addition of 6 μMR9 to eryth-
rocytes in Ringer exhibited weaker membrane staining and did not
show any aggregates (Fig. 5, SI Figure S5.2 and movie S5-M7). No cell
entrywas observed.Moreover, only aminor percentage of cells (around
4% from 2 different experiments, 595 cells in total) showed shape
changes and formed echinocytes (by 20 minutes) without exposure of
phosphatidylserine (SI Figure S5.2 andmovie S5-M7). CED, the dextran
backbone control, induced no changes in erythrocyte morphology
(SI, Figure S6). To explore to which degree the membrane aggregating
behavior of Dex-(R9)5 would extend to potential in vivo applications,
erythrocytes were also exposed to the conjugate in the presence of
human serum. Serum completely neutralized the effects of Dex-(R9)5
on erythrocytes observed in Ringer (SI, Figure S6).
3.3. Both, Dex-(R9)5 and R9 interfere with protein–protein interactions
involved in early T-cell signal transduction
The observations for Jurkat cells and erythrocytes demonstrated that
the multivalent display of R9 strongly potentiated the capacity tointeract with lipid membranes independent of the presence of heparan
sulfates. Clearly, on the linear backbone, multivalency yielded sufﬁcient
avidity to support interactions with the lipid head groups. Given a
recent report of interactions of arginine-rich peptides with microﬁla-
ments [45], we were interested to learn whether multivalency also
conferred an increased capacity to interfere with protein–protein inter-
actions. To this end, we took advantage of a peptide-based microarray
approach which we had used before to probe in parallel for signaling-
dependent changes in the formation of protein complexes in Jurkat
T cells [36]. The peptide arrays comprised a collection of
phosphotyrosine-containing and proline-rich peptides which interact
with SH2 and SH3 domains that play a major role in the organization
of signaling pathways [46,47]. Binding of proteins from cell lysates
was probed by indirect immunoﬂuorescence. We opted for PLCγ1 [48,
49] and the scaffold protein LAT [50,51], two important players in
early complex formation within T cell signaling, as indicators for a pos-
sible impact on protein–protein interactions. PLCγ1 can bind to pep-
tides on the microarray via its SH2 and SH3 domains. In contrast, LAT
can only bind as part of a protein complex as it has no suitable
domains to directly engage in interactions with peptides on the array.
LAT should therefore be a sensitive indicator for changes in protein–
protein interactions. In order to trigger signaling events and induce
formation of protein complexes, Jurkat cells were stimulated
with the broad-range phosphatase inhibitor pervanadate [52] or as
a control for resting cells treated with HBS only. Pervanadate leads
Fig. 6. Impact of R9 and Dex-(R9)5 on protein–protein interactions. Peptide microarrays were incubated with Jurkat cell lysates in the presence and absence of free R9 or the conjugate.
Colored squares indicate ratios of signals of treated cell lysates over untreated lysates on respective peptides and respective coefﬁcients of variation (CV). A cross relates to a signal thatwas
lost in the presence of peptide or conjugate. Cells were either resting (HBS) or stimulatedwith the broad-range phosphatase inhibitor pervanadate (PV). All data aremean values of three
independent experiments. Shown are those nine out of thirty one peptides on the arrays for which signals could be observed.
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domain-mediated complex formation. Addition of R9 and Dex-
(R9)5 caused the loss of several signals on proline-rich peptides but
not on phosphotyrosine-containing peptides (Fig. 6). Also LAT was
affected more strongly than PLCγ1 consistent with the indirect bind-
ing of LAT as part of a protein complex which provides several points
for interference with the interaction. However, there was little dif-
ference between R9 and Dex-(R9)5.
4. Discussion
Oligoarginines have gained ample attention as CPPs due to their high
internalization efﬁciency [24,25,53,54]. An increase of the valency of the
guanidino-group through amultivalent display of oligoarginines further
increases uptake efﬁciency [29]. So far, investigations of multivalency
have focused on uptake efﬁciency and intracellular trafﬁcking of globu-
lar molecular geometries [26]. For example, the tetravalent display of
the TAT CPP increased uptake efﬁciency by 1000-fold. Interestingly, to
this point there were no indications that the multivalent conﬁguration
conferred qualitatively new characteristics to the interaction of these
molecules with cells.
In this study, we linked on average ﬁve nona-arginine CPPs to a
linear dextran backbone. With this linear geometry, in a fully stretched
conformation this multivalent construct can engage plasma membrane
over a length of at least 25 nm (the dextran polymer backbone, Dex,
exhibits this length in the extended conformation [22]) and a width of
7 nm (two fully extended R9), yielding a maximal contact area of
175 nm2. In comparison, a streptavidin molecule which has been used
as a globular scaffold has a diameter of 5 nmwhich would be extended
by fully stretched peptides to 12 nm and thus an equivalent contact
area of 144 nm2. This similarity in size indicates that the observeddifferences must to a large extend be a consequence of the ﬂexibility
of the dextran backbone.
Remarkably, as derived from quantitative image analysis, uptake of
the conjugate, when related to peptide, was enhanced by a factor of
ﬁve at most in comparison of the free peptide. Therefore, this linear
arrangement of oligoarginines falls behind what was observed for the
globular conﬁgurations. However, very interestingly, this construct
showed the same imipramine-sensitive cytoplasmic uptake as the free
peptide, in spite of a totalmolecularweight of 22 kDa (CED+ peptides).
So far, observations by us [10] and others [9] had shown that this uptake
is restricted to small molecules only. In fact, elongation of nona-arginine
by only a heptapeptide strongly reduced the efﬁciency of this uptake
route. The molecular details of the nucleation zone-dependent uptake
still remain elusive. Based on the sphingomyelinase dependence and
the formation of ceramide, a lipid that forms membrane microdomains
[47], we proposed a model according to which peptides enter along
domain boundaries in a non-disruptive manner. Even though still
speculative in nature, the uptake that we observed here demonstrates
that a continuous display of arginines along a ﬂexible, linear scaffold
enables passage through these domain boundaries also for larger mole-
cules. It is tempting to assume that the peptides act like pearls on a
string. The ability to also drive larger molecules across the membrane
by this mechanism further supports a privileged role for arginines for
partitioning into lipid bilayers. Furthermore, local arginine density
instead of the absolute concentration of molecules is decisive in trigger-
ing this uptake route as in both cases the concentration of nona-arginine
was 20 μM.
Nevertheless, the nucleation zone dependent entry was super-
imposed by a stronger membrane-perturbation, demonstrating that a
covalent linkage to a linear scaffold is not equivalent to the addi-
tion as independent molecules. On HeLa cells, already at a peptide
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long-term toxicity over a period of 24 hours. This membrane-
disruptive capacity was even enhanced on Jurkat cells. Jurkat cells
possess only little glycocalyx [38]. While we cannot exclude that the
glycocalyx present on Jurkat cells mediates the observed interaction,
the strong membrane perturbation induced by the conjugate on
the Jurkat cells and enrichment in the plasma membrane indicates
that the peptide exerts a much stronger perturbating effect on the
lipid bilayer. It is reasonable to assume that this is a consequence of
the peptide gaining more readily access to the lipid bilayer and
interacting with lipid head groups. Exposure of negatively charged
phosphatidylserines further enhances this interaction. One may also
envision that an initial local exposure of phosphatidylserine further
promotes membrane association and thus membrane perturbation.
It is notable that the massive membrane staining was restricted to
Jurkat cells and also that for Jurkat cells, the conjugate did not gain
access to the cytoplasm. In our opinion, themost likelyway of reasoning
is that in Hela cells the conjugate induces rapid uptake and that interac-
tionswith the glycocalyx shield the lipid bilayer,while for Jurkat cells, in
the absence of a pronounced glycocalyx the perturbation of the lipid
bilayer dominates and the peptide is sequestered by the plasma mem-
brane and therefore not able to reach the cytosol.
Our results differ from those of Kawamura et al. [29], who showed
that the tetravalent display of deca-arginine at the N-terminus of the
p53 tetramerization domain did not confer any toxicity to CHO cells
at a peptide concentration of up to 25 μM for 4 hours. This discrep-
ancy suggests that a conformationally constrained arrangement of
oligoarginines as part of a macromolecule has a lower membrane-
disturbing potential, an observation in line with the absence of
toxicity of CPP-functionalized quantum dots [55] and nanoparticles
[56]. However, very interestingly, the capacity to engage in interac-
tions with the lipid bilayer by itself was not sufﬁcient for causing
severe toxicity. The dextran conjugate also strongly bound to and
even cross-linked erythrocytes. While this led to exposure of
phosphatidylserine in a considerable number of cells, there was no
disruption of cells and massive lysis.
In contrast, at a concentration of 6 μM, R9was completely indifferent
to erythrocytes. These observations demonstrate that with a higher
degree of multivalency, when linked to a linear scaffold, oligoarginine
acquires fundamentally new characteristics. Several articles have
reported on such aggregation behavior of erythrocytes being dependent
on the size and concentration of polymers such as dextran and also on
the surface charges on the erythrocyte membrane [57–59]. However,
theminimum size of dextran reported to cause erythrocyte aggregation
is 40 kDa at concentrations of 30–40 g/L corresponding to 750 μM-1mM
[57]. A smaller dextranwith 20 kDawas not able to induce any aggrega-
tion up to a concentration of 120 g/L corresponding to 6 mM [57].
For Dex-(R9)5 no cross-linking occurred in the presence of serum,
indicating a strong serum binding of the conjugate that competed for
membrane interactions [60] (SI, Figure S6). Erythrocytes do not possess
endocytosis and also lack sphingomyelinase demonstrating that the
increased toxicity for HeLa and Jurkat cells is a consequence of the
reaction of the nucleated cells towards the conjugate rather than a
membrane disruption caused by the physicochemical characteristics
of the conjugate. This is also supported by the reduced membrane
disruption for HeLa cells in which the sphingomyelinase-dependent
uptake had been abolished by imipramine treatment.
Since arginine-rich CPPs have already been shown to interact with
actin and stabilize stress ﬁbers [45], we set out to test whether R9 and
Dex-(R9)5 also had an impact on molecular interactions inside the
cell. We opted for our peptidemicroarray-based approach as it provides
a straightforward means to probe for the perturbation of several
interactions in parallel and furthermore also captures an impact on
the formation of signaling complexes. Both R9 and theDex-(R9)5 conju-
gate had a similar disturbing effect on interactionsmediated by proline-
rich peptides. It is difﬁcult to predict to which degree this disruptivepotential will be signiﬁcant in vivo. However, given the fact that
polyvalency did not increase the disrupting behavior, we consider it
highly unlikely that also at signiﬁcantly higher concentrations R9 will
severely disturb protein-protein interactions in cellular signaling. This
is also in accordance with the fact that the massive cytosolic import
that is observed for nucleation zone-dependent uptake does not cause
any acute toxicity or perturbation of cell structure.
5. Conclusions
In summary, our analyses show that for arginine-rich CPPs
multivalency on a linear scaffold affords a high avidity that critically
affects the interaction with cellular membranes. As demonstrated for
binding of R9 to erythrocytes, no binding is detected for the free
peptide while strong binding and also cross-linking into erythrocyte
stacks/aggregates occurs for the multivalent Dex-(R9)5 conjugate. For
HeLa and Jurkat cells, this multivalency strongly increases toxicity.
The observed toxicity for both cell lines demonstrates that this increase
in avidity is also observed for Jurkat cells with low levels of glycocalyx,
indicating that interactions with lipids play a more prominent role. In
addition, the membrane-disruptive behavior is a function of peptide
uptake and not of the conjugate alone. These results clearly demon-
strate that arginine-rich CPPs engage membrane structures just strong
enough to trigger uptake while avoiding detrimental multivalent inter-
actions that disturb membrane organization of larger areas.
Supplementary related to this article can be found online at http://
dx.doi.org/10.1016/j.bbamem.2014.08.001
Synthesis of Dex-(R9)5 (SI Figure S1.1, Figure S1.2, Table S1), whole
ﬁeld-view of cellular distribution and imipramine sensitive uptake of
Dex-(R9)5 in HeLa cells (SI Figure S2), effect of imipramine on peptide
internalization (SI Figure S3), time lapse microscopy movies showing
uptake in Jurkat cells (SImovies S4-M1 toM5), time lapsemovies show-
ing interaction of R9 and Dex-(R9)5 with erythrocytes (SI Figure S5.1,
S5.2 and movies S5-M6 to M7), confocal microscopy images showing
the effect of human serum on binding behavior of Dex-(R9)5 towards
human erythrocytes (SI Figure S6).
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